Fixed Duration Pirtobrutinib and Obinutuzumab in Chronic Lymphocytic Leukemia

Recruiting

Phase 2

Fixed Duration Pirtobrutinib and Obinutuzumab in Chronic Lymphocytic LeukemiaFixed Duration Pirtobrutinib and Obinutuzumab in Chronic Lymphocytic Leukemia

Sponsor:

Inhye Ahn

Code:

NCT06333262

Conditions

Chronic Lymphocytic Leukemia

Small Lymphocytic Lymphoma

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Pirtobrutinib

Obinutuzumab

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-03-31. This information was provided to ClinicalTrials.gov by Inhye Ahn on 2024-07-10.